Recent research indicates that patients with type 2 diabetes and obesity who received GLP-1 receptor agonists semaglutide or tirzepatide experienced significantly lower incidences of stroke, dementia, and all-cause mortality. Utilizing data from the TriNetX U.S. network, a cohort study with 60,860 adults over 40 was analyzed, revealing that users of these medications had lower risks compared to those on traditional antidiabetic treatments. The study results suggest these medications offer neuroprotective benefits, particularly in certain subgroups, thus highlighting their potential effectiveness in managing long-term cognitive and cerebrovascular health.

Source: JAMA Network